Oxford Nanopore Technologies sign Non-Exclusive licensing agreement Genetics Research

▴ Oxford Nanopore Technologies sign Non-Exclusive licensing agreement Genetics Research
Oxford Nanopore Technologies Sign Non-Exclusive Licensing Agreement for Genetics Research’s Patented DNA Negative Enrichment Technology Platform

Genetics Research, LLC (“GR”), a privately-held company developing a portfolio of novel and proprietary CRISPR-associated technologies for targeted DNA enrichment, announced today that it has licensed certain of its patents relating to this technology to Oxford Nanopore Technologies, Ltd. (“Oxford Nanopore”) based in Oxford, United Kingdom. This license enables Oxford Nanopore to use GR patents to enhance certain offerings on its proprietary nanopore DNA/RNA sequencing platform. Terms of the non-exclusive license agreement were not disclosed.

“We are delighted to have signed this agreement with Oxford Nanopore,” said Anthony P. Shuber, President and COO of GR. “This is one part of GR’s patent portfolio, which represents a completely new approach to targeting long DNA fragments for sequence-specific enrichment. Enriching sequence-specific long DNA is complementary to sequencing platforms with the capability to analyze long fragments, and we are excited that Oxford Nanopore will be integrating this method into certain workflows on its sequencing technology.”

“GR’s novel negative enrichment approach has exciting potential synergy with Oxford Nanopore’s platform,” commented Dr Gordon Sanghera, CEO of Oxford Nanopore. “Nanopore sequencing enables users to sequence native long fragments of nucleic acids, capturing multiple variants including complex structural variation and methylation in the same experiment. Delivering targeted approaches for these analyses allows users to focus on specific genomic regions that might be of interest, and to multiplex multiple samples in a single run. This offers users a roadmap to exploiting these novel markers in clinical research across large sample cohorts. Partnering with innovators like GR is important as we introduce new ways of performing rapid, near-sample targeted sequencing to the market.”

GR’s novel and proprietary CRISPR-based enrichment platform provide multiple opportunities to enhance the field of genomic analysis. In addition to its long DNA technologies, GR has developed next-generation targeted enrichment technologies that complement PCR and hybrid capture when applied to both long and short DNA fragments. These technologies have applications across both the life sciences and diagnostics spaces, including sequence-specific multiplex analyses in FFPE, and liquid biopsies.

Genetics Research develops innovative and proprietary technologies for the development of products supporting genomic analysis in research, diagnostics, and therapeutics. Oxford Nanopore was spun out of the University of Oxford and has since developed and brought to market a new generation of tools for biological analysis.

Tags : #OxfordNanoporeTechnologies #GeneticsResearch #NonExclusiveLicensingAgreement #LatestPharmanewsUpdatesSep23 #DNANegativeEnrichmentTechnology #DNATechnologies

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

10 PCOS Warning Signs That Need Your AttentionDecember 27, 2024
Experts Dub 2024 as the Year of Technologies and Innovations in Healthcare; Stress on further Integration of Technologies December 27, 2024
Aakash Healthcare Partners with Japan for Groundbreaking Surgical Intervention: A Global Collaboration to Revolutionize Cardiovascular CareDecember 26, 2024
Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024